| Literature DB >> 32369831 |
Yusuke Takada1,2, Daisuke Kamimura1, Jing-Jing Jiang1,3, Haruka Higuchi1,2, Daiki Iwami2, Kiyohiko Hotta2, Yuki Tanaka1, Mitsutoshi Ota1, Madoka Higuchi1,2, Saori Nishio4, Tatsuya Atsumi4, Nobuo Shinohara2, Yoshihiro Matsuno5, Takahiro Tsuji6, Tatsu Tanabe7, Hajime Sasaki7, Naoya Iwahara2, Masaaki Murakami1.
Abstract
Chronic active antibody-mediated rejection (CAAMR) is a particular problem in kidney transplantation (KTx), and ~25% of grafts are lost by CAAMR. Further, the pathogenesis remains unclear, and there is no effective cure or marker. We previously found that a hyper NFκB-activating mechanism in non-immune cells, called the IL-6 amplifier, is induced by the co-activation of NFκB and STAT3, and that this activation can develop various chronic inflammatory diseases. Here, we show that synaptotagmin-17 (SYT17) is increased in an exosomal fraction of the urine from CAAMR patients, and that this increase is associated with activation of the IL-6 amplifier. Immunohistochemistry showed that SYT17 protein expression was increased in renal tubule cells of the CAAMR group. While SYT17 protein was not detectable in whole-urine samples by western blotting, urinary exosomal SYT17 levels were significantly elevated in the CAAMR group compared to three other histology groups (normal, interstitial fibrosis and tubular atrophy, and calcineurin inhibitors toxicity) after KTx. On the other hand, current clinical laboratory data could not differentiate the CAAMR group from these groups. These data suggest that urinary exosomal SYT17 is a potential diagnostic marker for CAAMR. © The Japanese Society for Immunology. 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.Entities:
Keywords: chemokine; chronic rejection; cytokine; tubular cells
Year: 2020 PMID: 32369831 DOI: 10.1093/intimm/dxaa032
Source DB: PubMed Journal: Int Immunol ISSN: 0953-8178 Impact factor: 4.823